NEW YORK, NY / ACCESSWIRE / May 6, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.
Conduent Incorporated (NYSE: CNDT)
Class Period: February 21, 2018 - November 6, 2018
Lead Plaintiff Deadline : May 7, 2019
Join the action: https://www.zlk.com/pslra-1/conduent-incorporated-loss-form?prid=1414&wire=1
The complaint alleges that by February 2018, defendants began to represent to investors that Conduent had exited the transformation phase and had cured inefficiencies caused by operating on multiple information resource platforms. However, as demonstrated by defendants' admissions on November 7, 2018, those representations were false, and Conduent remained mired in inadequate technology and third-party agreements that it had been saddled with upon its divestiture from Xerox.
During a November 7, 2018 conference call, CEO Ashok Vemuri stated ''we have had continued suboptimal performance from an inherited legacy technology vendor. The performance issues stem from the vendors inability to deliver on service level agreements, lack of responsiveness to Conduent's needs, and poorly structured contracts which we inherited.'' Vemuri also noted that an ''outdated and historically under-invested legacy IT infrastructure has caused major disruptions to our operations and impacted client and delivery performance.''
To learn more about the Conduent Incorporated class action contact jlevi@levikorsinsky.com.
American Renal Associates Holdings, Inc. (NYSE: ARA)
Class Period: August 10, 2016 - March 27, 2019
Lead Plaintiff Deadline : May 28, 2019
Join the action: https://www.zlk.com/pslra-1/american-renal-associates-holdings-inc-loss-form?prid=1414&wire=1
About the lawsuit: Throughout the class period, American Renal Associates Holdings, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) issues with American Renal's accounting process for revenue recognition, collections, and related matters would give rise to a U.S. Securities and Exchange Commission (''SEC'') investigation into the same, and increased regulatory scrutiny by the SEC; (2) financial statements for the fiscal years 2014, 2015, 2016 and 2017 contained in its Annual Reports for the years ended December 31, 2016 and 2017, and its condensed consolidated financial statements in quarterly reports from 2016 through 2018, were false and could not be relied upon; (3) American Renal had material weaknesses in its internal control over financial reporting; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times.
To learn more about the American Renal Associates Holdings, Inc. class action contact jlevi@levikorsinsky.com.
Apple Inc. (NASDAQGS: AAPL)
Class Period: November 2, 2018 - January 2, 2019
Lead Plaintiff Deadline : June 17, 2019
Join the action: https://www.zlk.com/pslra-1/apple-inc-loss-form?prid=1414&wire=1
About the lawsuit: Apple Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) the U.S.-China trade war had negatively impacted demand for iPhones and Apple's pricing power in greater China, one of Apple's most important growth markets; (b) the rate at which Apple customers were replacing their batteries in older iPhones rather than purchasing new iPhones was negatively impacting Apple's iPhone sales growth; (c) as a result of slowing demand, Apple had slashed production orders from suppliers for the new 2018 iPhone models and cut prices to reduce inventory; (d) unit sales for iPhone and other hardware was relevant to investors and the Company's financial performance, and the decision to withhold such unit sales was designed to and would mask declines in unit sales of the Company's flagship product; and (e) as a result of the foregoing, defendants lacked a reasonable basis in fact when issuing the Company's revenue outlook for the first quarter 2019 and/or making the related statements concerning demand for its products, as Apple's business metrics and financial prospects were not as strong as defendants had led the market to believe.
To learn more about the Apple Inc. class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/544407/CLASS-ACTION-UPDATE-for-CNDT-ARA-and-AAPL-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
